TL;DR
The AdvisorShares Pure US Cannabis ETF (MSOS) closed Tuesday at $4.49 (+0.67%) and pushed to $4.55 in after-hours trading (+1.34%), extending the day’s gains as Q2 earnings dates for the sector’s largest MSOs come into view. Volume came in at 3.49 million shares — well below the 90-day average of 9.15 million — suggesting Tuesday’s advance reflects disciplined accumulation rather than speculative momentum. With Green Thumb Industries (GTBIF) reporting Q2 results on August 4 and Curaleaf Holdings (CURLF) following on August 5, the cannabis sector enters a critical three-week earnings window that will reset price expectations across the MSO complex.
Market Analysis
Tuesday’s MSOS session opened at $4.47 and reached an intraday high of $4.57 before settling at the close of $4.49. The day’s low of $4.42 held cleanly above recent support levels, preserving a higher-low structure that has defined the ETF’s short-term technical posture since the beginning of July. The after-hours move to $4.55 represented an additional $0.06 gain — a meaningful increment in a sector ETF where institutional positioning often plays out in the extended session.
Volume was the defining data point of Tuesday’s tape. At 3.49 million shares, turnover came in at roughly 38% of the 90-day average of 9.15 million. In most market contexts, low-volume advances invite skepticism. In the cannabis sector, however, light volume on up days frequently reflects the absence of motivated sellers rather than weak conviction among buyers. The bid-ask spread into close — $4.47 bid against a $4.50 ask on approximately 1.19 million shares offered — confirmed that supply was orderly rather than elevated. That profile, combined with the after-hours extension, points toward a setup where Wednesday’s opening volume will carry significant informational weight: sustained buying on normalized volume would confirm that Tuesday’s move was the beginning of a fresh leg rather than a low-conviction drift.
MSOS currently sits at $4.55 in after-hours trading, a 38% discount to the 52-week high of $7.25 and an 83% premium over the 52-week low of $2.48. The 1-year return of +61.59% against a year-to-date figure of -5.51% reflects a sector that made significant gains in late 2025 and early 2026 but has consolidated through mid-year. That consolidation phase now appears to be testing its lower boundary as the earnings catalyst cycle approaches.
Regulatory and Market Context
The Q2 earnings calendar is the dominant short-term catalyst for the cannabis equity complex. Green Thumb Industries, which anchors the sector’s profitability narrative, reports on August 4. GTBIF’s most recent financials reflect trailing-twelve-month revenue of approximately $1.2 billion, earnings per share of $0.51, and a trailing P/E of 14.90 — metrics that are structurally unusual for a cannabis operator and that underpin the analyst consensus target of $15.67 against a current price near $7.60. The implied upside of over 100% against a profitable, cash-generating operator represents a risk-reward profile that becomes increasingly difficult for institutional capital allocators to ignore as the earnings date approaches.
Curaleaf Holdings, the single largest weighting in MSOS at 12.18% of fund assets, reports one day later on August 5. Despite carrying a net loss on a trailing basis, CURLF has delivered a 12-month return of approximately 158%, reflecting a market rerating driven by revenue scale ($1.29 billion trailing twelve months), free cash flow generation ($82 million levered), and ongoing restructuring that has streamlined the company’s domestic footprint. Curaleaf’s Q2 report will be the most closely watched event in the sector this earnings cycle — and its trajectory will disproportionately influence MSOS performance in the days following the release.
Federal regulatory momentum remains a structural backdrop. The DEA’s Schedule III rescheduling proceeding, while not finalized, continues to move through procedural review. Each step forward in that process reduces the binary risk premium embedded in cannabis equity valuations — a tailwind that compounds with every quarter of improved fundamentals from operators like Green Thumb and Curaleaf.
Conclusion
Wednesday’s session opens with MSOS at $4.55 in after-hours, positioned just below Tuesday’s intraday high of $4.57. A clean break above that level on volume approaching the 90-day average would represent a meaningful technical confirmation that the sector is resuming its upward trajectory into the Q2 earnings window. Failure to hold $4.49 on the open would invite a retest of the $4.42 intraday low established Tuesday.
Investors tracking the MSO earnings cycle should mark August 4 and August 5 on their calendars now. The convergence of two large-cap MSO reports within a 24-hour window is a rare setup — and one that historically generates significant volatility in underlying positions and the MSOS ETF alike. The three weeks ahead represent the clearest near-term catalyst window of the year. Investors monitoring the cannabis stock tracker should watch MSOS volume normalization as the primary signal that pre-earnings positioning is actively underway.